Paper38337010
Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.
Muluhie M and 5 others. Sci Rep, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction. Papers, record 38337010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38337010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ventricular Remodeling | Major topic |
| Myocardial Infarction | Major topic |
| Acetates | Major topic |
| Cyclopropanes | Major topic |
| Quinolines | Major topic |
| Sulfides | Major topic |
| Mice | |
| Animals | |
| Female | |
| Mice, Inbred C57BL | |
| Myocardium |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30310233 | Drug repurposing: progress, challenges and recommendations. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30310233 | PubMed |
| 2 | 30513339 | The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. | Drug Discov Today | 2019 | https://conductscience.org/library/papers/30513339 | PubMed |
| 3 | 18949546 | Leukotriene signaling in atherosclerosis and ischemia. | Cardiovasc Drugs Ther | 2009 | https://conductscience.org/library/papers/18949546 | PubMed |
| 4 | 20093252 | The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. | Cardiovasc Res | 2010 | https://conductscience.org/library/papers/20093252 | PubMed |
| 5 | 22434418 | Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. | Med Res Rev | 2013 | https://conductscience.org/library/papers/22434418 | PubMed |
| 6 | 28246014 | Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosis. | Biochem Biophys Res Commun | 2017 | https://conductscience.org/library/papers/28246014 | PubMed |
| 7 | 18953103 | The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. | J Physiol Pharmacol | 2008 | https://conductscience.org/library/papers/18953103 | PubMed |
| 8 | 19110249 | Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. | Atherosclerosis | 2009 | https://conductscience.org/library/papers/19110249 | PubMed |
| 9 | 19998057 | Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits. | Cardiovasc Drugs Ther | 2009 | https://conductscience.org/library/papers/19998057 | PubMed |
| 10 | 29432192 | Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29432192 | PubMed |
| 11 | 22527886 | Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. | J Mol Med (Berl) | 2012 | https://conductscience.org/library/papers/22527886 | PubMed |
| 12 | 31313075 | Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier. | Inflammopharmacology | 2019 | https://conductscience.org/library/papers/31313075 | PubMed |
| 13 | 16990797 | The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. | EMBO J | 2006 | https://conductscience.org/library/papers/16990797 | PubMed |
| 14 | 30818044 | Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug. | Pharmacol Res | 2019 | https://conductscience.org/library/papers/30818044 | PubMed |
| 15 | 22244598 | Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. | J Allergy Clin Immunol | 2012 | https://conductscience.org/library/papers/22244598 | PubMed |
| 16 | 33519477 | Montelukast Use Decreases Cardiovascular Events in Asthmatics. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33519477 | PubMed |
| 17 | 17646220 | The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. | Chest | 2007 | https://conductscience.org/library/papers/17646220 | PubMed |
| 18 | 21112334 | Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury. | J Mol Cell Cardiol | 2011 | https://conductscience.org/library/papers/21112334 | PubMed |
| 19 | 26089034 | Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats. | Hum Exp Toxicol | 2016 | https://conductscience.org/library/papers/26089034 | PubMed |
| 20 | 35358494 | Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. | Eur J Pharmacol | 2022 | https://conductscience.org/library/papers/35358494 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42401692 | Molecular mechanisms of coronary microembolization-induced MINOCA. | Basic Res Cardiol | 2026 | https://conductscience.org/library/papers/42401692 | PubMed |
| 41870545 | Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41870545 | PubMed |
| 40715741 | New insights on pharmacological potential of montelukast: a comprehensive review. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/40715741 | PubMed |
| 40512240 | Molecular screening in a translational large animal trial identifies a differential inflammatory response for MINOCA. | Basic Res Cardiol | 2025 | https://conductscience.org/library/papers/40512240 | PubMed |
| 40234645 | Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation. | Sci Rep | 2025 | https://conductscience.org/library/papers/40234645 | PubMed |
| 39327397 | Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. | Drugs | 2024 | https://conductscience.org/library/papers/39327397 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38337010
GET https://conductscience.org/api/papers/v1/38337010/references?page=2